IQVIA Helps Drive US Health Economics and Outcomes Research Services from USD 2.8 billion in 2026 to USD 7.9 billion by 2036 at 10.9% CAGR

ROCKVILLE, MARYLAND , August 11, 2026 - The Health Economics and Outcomes Research (HEOR) Services market reached USD 2.5 billion in 2025. Demand is forecast to rise from USD 2.8 billion in 2026 to USD 7.9 billion by 2036 at a compound annual growth rate (CAGR) of 10.9%, creating an absolute opportunity of USD 5.1 billion.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15997

Key Findings

Market value: USD 2.5 billion (2025), USD 2.8 billion (2026), USD 7.9 billion (2036).
CAGR (2026-2036): 10.9%.
Absolute opportunity by 2036: USD 5.1 billion.
Leading service offering (2026): Health Economics Studies at 39.0% share.
Leading application (2026): Cost-effectiveness Analysis at 36.0% share.
Leading end user (2026): Pharmaceutical Companies at 41.0% share.
Leading delivery model (2026): Project-based Services at 48.0% share.
Leading research methodology (2026): Decision Analytic Modeling at 44.0% share.

Growth Drivers

Payer evidence requirements: Coverage teams seek proof that treatment benefits justify reimbursement and budget impact. In January 2026, the Centers for Medicare & Medicaid Services (CMS) selected 15 high-cost Medicare Part B and Part D drugs for the third negotiation cycle; these drugs were used by about 1.8 million Medicare beneficiaries from November 2024 to October 2025 and accounted for about USD 27 billion in Medicare spending.
Launch-stage value planning: Sponsors prepare cost-effectiveness models before pricing discussions. The Organisation for Economic Co-operation and Development reported in 2025 that OECD countries spent 9.3% of GDP on health in 2024.
Real-world evidence use: Post-trial data strengthen value arguments in routine care.
Digital evidence workflows: Tools shorten literature review and model-testing cycles.
HTA submission complexity: Medium-term impact in Europe, Japan and Australia.
Relative impact is highest for payer evidence requirements and launch-stage value planning (North America and Europe, short term).

Segment Analysis by Product, Technology and Application

Service Offering

Health Economics Studies: 39.0% share in 2026 (includes cost-effectiveness modeling and budget impact analysis).
Real-world Evidence Services (patient registry studies, claims database analysis).
Market Access Services (pricing & reimbursement strategy, health technology assessment dossiers).
Patient-reported Outcomes Services (PRO instrument development and validation).

Application

Cost-effectiveness Analysis: 36.0% share in 2026 (health technology assessment, reimbursement submission).
Post-marketing Outcomes Research (patient safety evaluation, comparative effectiveness research).
Value Demonstration (payer evidence generation, reimbursement negotiation support).
Clinical Outcomes Assessment (quality of life and treatment satisfaction assessment).

End User

Pharmaceutical Companies: 41.0% share in 2026.
Contract Research Organizations.
Government Agencies.
Hospitals.

Delivery Model

Project-based Services: 48.0% share in 2026 (launch evidence and reimbursement submission projects).
Outsourced Research Services.
Strategic Advisory Services.
Digital Research Platforms.

Research Methodology

Decision Analytic Modeling: 44.0% share in 2026 (Markov modeling, discrete event simulation).
Observational Study Analytics.
Health Technology Assessment Frameworks.
Patient-centered Outcomes Research.
EMA's 2025 annual report shows the agency recommended 104 medicines for marketing authorisation in 2025, including 38 with new active substances, supporting ongoing pharmaceutical demand for access evidence.

Country-Level Growth Comparison

Country

CAGR (2026-2036)

One-line commercial condition

USA

11.8%

Large payer networks require budget-impact arguments; 2024 U.S. health spending reached USD 15,474 per person and 18.0% of GDP.

Germany

11.4%

Reimbursement reviews emphasize comparative evidence and local adaptation of global value models.

UK

10.9%

Clear cost-effectiveness reasoning required before access decisions; models must fit national review expectations.

Canada

10.5%

Public-plan reviews examine clinical value and affordability; submissions must translate trial outcomes into budget terms.

France

10.0%

Evidence must compare new therapies with established pathways under local access-review rules.

Japan

9.6%

Clinical evidence must connect to care-cost pressure in mature settings with local interpretation.

Australia

9.2%

Clear clinical and economic reasoning required to balance patient outcomes with payer affordability.

The range between the USA (11.8%) and Australia (9.2%) is 2.6 percentage points. USA, Germany, UK and Canada form the higher-growth group.

Competitive Landscape

Key providers offering HEOR, real-world evidence, health-economic modelling or market-access services include:

IQVIA Holdings Inc.
ICON plc
Syneos Health, Inc.
Parexel International Corporation
Cytel Inc.
RTI Health Solutions
Oracle Corporation (Oracle Life Sciences)
Costello Medical
Axtria Inc.
Providers compete on HEOR design, modelling capability and local market-access knowledge. The competitive analysis profiles these companies without assigning share estimates.

Recent Developments

January 2026: CMS selected 15 high-cost Medicare Part B and Part D drugs for the third negotiation cycle (≈1.8 million beneficiaries, ≈USD 27 billion spending November 2024-October 2025).
2025: EMA recommended 104 medicines for marketing authorisation, including 38 with new active substances.
2025: OECD reported OECD countries spent 9.3% of GDP on health in 2024.
CMS reported 2024 U.S. health spending of USD 15,474 per person (18.0% of GDP).
No specific company funding rounds, partnerships or acquisitions are detailed in the source report beyond the listed providers.

Restraints

Data access limits (high impact, global, short term): Claims data and registries are often difficult to obtain; patient-reported outcomes add collection barriers.
Model transparency concerns (medium impact, HTA-led markets, short term): Payers challenge unclear assumptions or weak sensitivity testing.
Country-specific payer rules (medium impact, Europe, Japan, Australia, medium term).
Specialist talent constraints (medium impact, emerging service markets, long term).

How to Choose

Procurement and R&D teams evaluating HEOR providers should apply these criteria drawn directly from market structure and buyer requirements:

Confirm capability in Health Economics Studies and Decision Analytic Modeling (the 39.0% and 44.0% share leaders in 2026).
Verify experience generating Cost-effectiveness Analysis packages aligned with payer and HTA requirements (36.0% application share).
Assess ability to deliver project-based services around defined reimbursement milestones (48.0% delivery-model share).
Require demonstrated local adaptation of evidence packages for target countries (USA 11.8% CAGR, Germany 11.4%, UK 10.9%, etc.).
Evaluate integration of real-world evidence and digital tools to shorten literature-review and model-testing cycles.
Align vendor selection with market-access teams so final packages address specific payer questions rather than generic value claims.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/health-economics-and-outcomes-research-services-market

Report Scope

The report covers the period 2026-2036 and quantifies the market at USD 2.8 billion in 2026 rising to USD 7.9 billion by 2036 at 10.9% CAGR. Segments include service offering (Health Economics Studies, Real-world Evidence Services, Market Access Services, Patient-reported Outcomes Services), application, end user, delivery model, research methodology, and the regions North America, Latin America, Europe, Asia Pacific, and Middle East & Africa, with country detail for the USA, Germany, UK, Canada, France, Japan and Australia. Key companies profiled are IQVIA Holdings Inc., ICON plc, Syneos Health, Inc., Parexel International Corporation, Cytel Inc., RTI Health Solutions, Oracle Corporation (Oracle Life Sciences), Costello Medical and Axtria Inc.

Explore More Related Studies Published by Fact.MR Research

Decentralized Clinical Trials Contract Research Organization CRO Market- https://www.factmr.com/report/decentralized-clinical-trials-contract-research-organization-cro-market

Edge AI Medical Software Market- https://www.factmr.com/report/edge-ai-medical-software-market

Artificial Intelligence in Ultrasound Imaging Market- https://www.fortunebusinessinsights.com/ai-in-ultrasound-imaging-market-115854

Gram Positive Bacterial Infections Treatment Market- https://www.factmr.com/report/gram-positive-bacterial-infections-treatment-market

Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dis

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.